PMID- 25828037
OWN - NLM
STAT- MEDLINE
DCOM- 20150605
LR  - 20150401
IS  - 1524-4725 (Electronic)
IS  - 1076-0512 (Linking)
VI  - 41 Suppl 1
DP  - 2015 Apr
TI  - A randomized, evaluator-blinded, controlled study of effectiveness and safety of 
      small particle hyaluronic acid plus lidocaine for lip augmentation and perioral 
      rhytides.
PG  - S127-36
LID - 10.1097/DSS.0000000000000199 [doi]
AB  - OBJECTIVE: To compare the safety and effectiveness of small particle hyaluronic 
      acid plus lidocaine (SPHAL) versus no treatment for lip augmentation and perioral 
      rhytides. METHODS AND MATERIALS: Adults scoring 1 (very thin) to 2 (thin) on the 
      Medicis Lip Fullness Scale (MLFS) for upper and lower lips were randomized (3:1) 
      to SPHAL or no treatment. Treatment success was an MLFS increase >/=1 point at Week 
      8. Secondary end points (MLFS score, independent photographic review, Global 
      Aesthetic Improvement Scale, Wrinkle Assessment Scale for Upper Lip Lines) and 
      safety were assessed throughout. RESULTS: Statistically significantly more 
      patients were treatment successes with SPHAL (upper lip [80.2% vs 11.9%], lower 
      lip [84.2% vs 18.4%], and upper and lower lips combined [76.1% vs 11.6%]), 
      compared with no treatment (p <.001, all outcomes). Patients treated for both lip 
      augmentation and perioral rhytides were rated as having an aesthetically 
      meaningful improvement in perioral rhytides (p <.001). Most common 
      treatment-emergent adverse events (AEs) included lip bruising, swelling, and pain 
      and were mostly mild and transient in nature, without anticipated device AEs. 
      CONCLUSION: Small particle hyaluronic acid plus lidocaine was effective and well 
      tolerated and significantly more effective when both lips and perioral rhytides 
      were treated, with improvement evident up to 6 months after treatment.
FAU - Beer, Kenneth
AU  - Beer K
AD  - *Department of Dermatology, University of Pennsylvania, Philadelphia, 
      Pennsylvania; daggerDepartment of Dermatology, University of California, San 
      Francisco, California; double daggerDepartment of Dermatology, Yale University School of 
      Medicine, New Haven, Connecticut;  section signDepartment of Dermatology, Geffen School of 
      Medicine, University of California Los Angeles, Los Angeles, California;  ||Valeant 
      Aesthetics, a Division of Valeant Pharmaceuticals North America LLC, Bridgewater, 
      New Jersey;  paragraph signInergy Limited, Lindfield, United Kingdom.
FAU - Glogau, Richard G
AU  - Glogau RG
FAU - Dover, Jeffrey S
AU  - Dover JS
FAU - Shamban, Ava
AU  - Shamban A
FAU - Handiwala, Lata
AU  - Handiwala L
FAU - Olin, Jason T
AU  - Olin JT
FAU - Bulley, Brian
AU  - Bulley B
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Dermatol Surg
JT  - Dermatologic surgery : official publication for American Society for Dermatologic 
      Surgery [et al.]
JID - 9504371
RN  - 0 (Anesthetics, Local)
RN  - 0 (Gels)
RN  - 9004-61-9 (Hyaluronic Acid)
RN  - 98PI200987 (Lidocaine)
SB  - IM
MH  - Adolescent
MH  - Aged
MH  - Anesthetics, Local/*administration & dosage/adverse effects
MH  - Contusions/chemically induced
MH  - *Cosmetic Techniques
MH  - Edema/chemically induced
MH  - Female
MH  - Gels
MH  - Humans
MH  - Hyaluronic Acid/*administration & dosage/adverse effects
MH  - Injections, Intradermal
MH  - Lidocaine/*administration & dosage/adverse effects
MH  - *Lip
MH  - Male
MH  - Middle Aged
MH  - Pain/chemically induced
MH  - Particle Size
MH  - Rejuvenation
MH  - *Skin Aging
MH  - Young Adult
EDAT- 2015/04/02 06:00
MHDA- 2015/06/06 06:00
CRDT- 2015/04/02 06:00
PHST- 2015/04/02 06:00 [entrez]
PHST- 2015/04/02 06:00 [pubmed]
PHST- 2015/06/06 06:00 [medline]
AID - 00042728-201504001-00003 [pii]
AID - 10.1097/DSS.0000000000000199 [doi]
PST - ppublish
SO  - Dermatol Surg. 2015 Apr;41 Suppl 1:S127-36. doi: 10.1097/DSS.0000000000000199.